Ata uhi

Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action

Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....

Whakaahuatanga katoa

I tiakina i:
Hōputu: Online
Reo:Ingarihi
I whakaputaina: MDPI - Multidisciplinary Digital Publishing Institute 2022
Ngā marau:
microtubule acetylation
triple-negative breast cancer
anti-cancer agent
apoptosis
K562
8-hydroxydaidzein
autophagy
BCR-ABL
MAPK
NF-κB
c-myc
RNA interference
siRNA
oncogene
gene silencing
expression
nanosystems
Cytochrome P450
CYP1A1
CYP1B1
CYP2W1
breast cancer
prodrug
bioprecursor
duocarmycin
phortress
AQ4N
5-FU resistance
colorectal cancer
drug repurposing
Genomics of Drug Sensitivity in Cancer
Connectivity Map
anticancer drug
B-lactam steroid alkylators
synthetic lethality
poly (ADP-ribose) polymerase inhibitors
ovarian cancer
hybrid steroidal alkylating agents
migration
invasion
glioblastoma
CCN1
mesenchymal–amoeboid transition
biomarker
HepG2
Huh7
isatin sulfonamides
angiogenesis
cancer hallmarks
molecular docking
EGFR tyrosine kinase inhibitor
photon upconversion
triplet-triplet annihilation
in vivo imaging
PLGA
nanoparticles
affibody molecule
human epidermal growth factor receptor 3 (HER3)
BxPC-3
emtansine
DM1
albumin binding domain
affibody drug conjugate (AffiDC)
n/a
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues::TBX History of engineering and technology
Urunga tuihono:ONIX_20221025_9783036552217_68
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
Me noho koe te mea tuatahi ki te waiho tākupu!
Me takiuru i te tuatahi

Ngā tūemi rite